Filing Details
- Accession Number:
- 0001209191-12-008147
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-02-07 16:29:32
- Reporting Period:
- 2012-02-06
- Filing Date:
- 2012-02-07
- Accepted Time:
- 2012-02-07 16:29:32
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1298332 | Matthew Emmens | C/O Vertex Pharmaceuticals Incorporated 130 Waverly St Cambridge MA 02139 | Executive Chairman | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2011-02-06 | 2,500 | $36.39 | 265,101 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-02-06 | 12,900 | $37.11 | 252,201 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-02-06 | 40,600 | $38.08 | 211,601 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to Mr. Emmens' company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $36.39 (range $35.64 to $36.61).
- Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $37.11 (range $36.68 to $37.67).
- Open market sales reported on this line occurred at a weighted average price of $38.08 (range $37.70 to $38.33).